high-risk localized and locally advanced renal cell carcinoma
Conditions
Interventions
Test group:Iparomlimab and Tuvonralimab
Sponsors
Shandong Provincial Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Voluntarily signed written informed consent (ICF); 2.18=3 months; 8. Good vital organ function and bone marrow status; 9. Subject is willing and able to comply with scheduled visits, treatment protocol, laboratory tests, and other study requirements.
Exclusion criteria
Exclusion criteria: 1. Poor general condition, anesthesia evaluation cannot tolerate general anesthesia surgery; 2. Severe cardiovascular and cerebrovascular disease, uncontrolled hypertension and diabetes; 3. Patients who have been using immunosuppressants for a long time after organ transplantation or who are using immunosuppressive drugs; 4. Patients with other malignant tumors, or who are being treated for other benign malignancies, or who have a history of other malignancies in the past six months; 5. Received traditional Chinese medicine treatment with anti-tumor or immunomodulatory effects within 14 days before the first use of study drug; or have received systemic treatment (including thymus, interferon, interleukin, etc., except for topical use to control pleural effusion); 6. Active or likely recurrent autoimmune diseases, except vitiligo, alopecia, psoriasis, or eczema that do not require systematic treatment; 7. Concurrent participation in another clinical study, unless it is an observational, non-interventional clinical study or follow-up period of an interventional study; 8. Known history of mental illness, drug abuse, alcohol or drug use; 9. Pregnant or breastfeeding women; 10. There are any other factors that may confound the results of the study, interfere with the subject's full participation in the study, or the investigator believes that the subject is not suitable for participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival, OS;AE;Pathological complete response rate, pCR;Event-free survival, EFS; | — |
Countries
China
Contacts
Public ContactQinghua Xia
Shandong Provincial Hospital
Outcome results
None listed